​

United Therapeutics (UTHR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

UTHR Stock Forecast

United Therapeutics (UTHR) stock forecast, based on 31 Wall Street analysts, predicts a 12-month average price target of $651.63, with a high of $735.00 and a low of $368.00. This represents a 11.43% increase from the last price of $584.79.

$350 $430 $510 $590 $670 $750 High: $735 Avg: $651.63 Low: $368 Last Closed Price: $584.79

UTHR Stock Rating

United Therapeutics stock's rating consensus is Buy, based on 31 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 19 Buy (61.29%), 11 Hold (35.48%), 1 Sell (3.23%), and 0 Strong Sell (0.00%).

Buy
Total 31 1 11 19 Strong Sell Sell Hold Buy Strong Buy

UTHR Price Target Upside V Benchmarks

TypeNameUpside
StockUnited Therapeutics11.43%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts8921
Avg Price Target$624.00$611.89$605.67
Last Closing Price$584.79$584.79$584.79
Upside/Downside6.70%4.63%3.57%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 263831-15
Sep, 26383--14
Aug, 26393--15
Jul, 26393--15
Jun, 26393--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 22, 2026RBC Capital$697.00$577.0520.79%19.19%
Oct 20, 2026Raymond James$717.00$564.1527.09%22.61%
Oct 19, 2026UBS$725.00$533.1235.99%23.98%
Oct 15, 2026Goldman Sachs$368.00$540.03-31.86%-37.07%
Oct 14, 2026Roger SongJefferies$728.00$543.4033.97%24.49%
Oct 08, 2026RBC Capital$708.00$533.8632.62%21.07%
Oct 01, 2026BTIG$728.00$541.8934.34%24.49%
Sep 24, 2026Andrea NewkirkGoldman Sachs$321.00$489.42-34.41%-45.11%
Aug 06, 2026Terence FlynnMorgan Stanley$515.00$519.01-0.77%-11.93%
May 07, 2026Terence FlynnMorgan Stanley$516.00$583.15-11.52%-11.76%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 20, 2026Raymond JamesOutperformOutperformhold
Oct 15, 2026Goldman SachsSellSellhold
Oct 14, 2026JefferiesBuyBuyhold
Oct 08, 2026RBC CapitalOutperformOutperformhold
Oct 01, 2026Cantor FitzgeraldOverweightOverweighthold
Oct 01, 2026BTIGBuyBuyupgrade
Sep 24, 2026Goldman SachsNeutralSellinitialise
May 21, 2026Cowen & Co.BuyBuyhold
May 07, 2026BarclaysOverweightupgrade
May 07, 2026Wells FargoBuyOverweightupgrade

Financial Forecast

EPS Forecast

$10 $21 $32 $43 $54 $65 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.60$15.98$21.04$26.44$30.13---
Avg Forecast$11.38$17.52$19.75$24.31$28.54$29.58$39.69$34.70
High Forecast$12.10$18.72$21.10$28.47$34.53$41.57$61.71$37.76
Low Forecast$10.42$15.82$18.78$22.59$22.69$17.20$23.50$30.22
Surprise %-6.85%-8.79%6.53%8.76%5.57%---

Revenue Forecast

$2B $2B $3B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.69B$1.94B$2.33B$2.88B$3.18B---
Avg Forecast$1.70B$1.96B$2.29B$2.88B$3.17B$3.37B$3.87B$4.11B
High Forecast$1.78B$2.07B$2.33B$2.95B$3.38B$3.38B$3.96B$4.39B
Low Forecast$1.59B$1.82B$2.26B$2.84B$2.87B$3.36B$3.78B$3.70B
Surprise %-0.73%-1.35%1.66%0.02%0.38%---

Net Income Forecast

$0 $700M $1B $2B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$475.80M$727.30M$984.80M$1.20B$1.33B---
Avg Forecast$484.39M$532.82M$984.80M$1.27B$1.30B$1.29B$1.61B$1.72B
High Forecast$581.26M$639.39M$1.18B$1.42B$1.72B$2.07B$3.07B$1.88B
Low Forecast$387.51M$426.26M$787.84M$1.12B$1.13B$854.73M$1.17B$1.50B
Surprise %-1.77%36.50%--5.83%2.34%---

UTHR Forecast FAQ

Is United Therapeutics stock a buy?

United Therapeutics stock has a consensus rating of Buy, based on 31 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 19 Buy, 11 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that United Therapeutics is a favorable investment for most analysts.

What is United Therapeutics's price target?

United Therapeutics's price target, set by 31 Wall Street analysts, averages $651.63 over the next 12 months. The price target range spans from $368 at the low end to $735 at the high end, suggesting a potential 11.43% change from the previous closing price of $584.79.

How does United Therapeutics stock forecast compare to its benchmarks?

United Therapeutics's stock forecast shows a 11.43% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for United Therapeutics over the past three months?

  • October 2026: 20.00% Strong Buy, 53.33% Buy, 20.00% Hold, 6.67% Sell, 0% Strong Sell.
  • September 2026: 21.43% Strong Buy, 57.14% Buy, 21.43% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is United Therapeutics’s EPS forecast?

United Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $29.58, marking a -1.83% decrease from the reported $30.13 in 2025. Estimates for the following years are $39.69 in 2027, and $34.7 in 2028.

What is United Therapeutics’s revenue forecast?

United Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $3.37B, reflecting a 5.90% increase from the reported $3.18B in 2025. The forecast for 2027 is $3.87B, and $4.11B for 2028.

What is United Therapeutics’s net income forecast?

United Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $1.29B, representing a -3.34% decrease from the reported $1.33B in 2025. Projections indicate $1.61B in 2027, and $1.72B in 2028.